FDA Aims To “NSURE” Clarity About New Paradigm For OTC Switches
This article was originally published in The Tan Sheet
Executive Summary
FDA official Rikin Mehta assures stakeholders that the proposed new paradigm for Rx-to-OTC switches would not create a third class of drugs, give pharmacists prescribing power or eliminate the need for consumers to visit doctors.
You may also be interested in...
Innovation In OTC Switches Takes Multimedia Approach In US FDA Draft Guidance
Sponsors can point consumers to video displays, website information and mobile apps to help them choose products that have been switched from Rx to OTC. Draft guidance on innovative switch applications to be followed by rule-making in near future.
Innovation In OTC Switches Takes Multimedia Approach In US FDA Draft Guidance
Sponsors can point consumers to video displays, website information and mobile apps to help them choose products that have been switched from Rx to OTC. Draft guidance on innovative switch applications to be followed by rule-making in near future.
Technology Gap Separates OTC Drug Firms From Self-Care Sales Growth
OTC drug firms should offer more digital tools that guide consumers in product purchases, says a health care marketing executive. The American Pharmacists Association suggests firms also strengthen outreach with pharmacists.